生长抑素受体PET疗效评估框架(SSTR-PeRForm V1.0)
本政策综述报告了欧洲神经内分泌肿瘤学会通过改良德尔菲法制定的生长抑素受体PET疗效评估框架。34位国际专家经四轮迭代评估76条声明,共识定义为至少75%同意。框架提出主要依据生长抑素受体表达靶病灶的体积变化并辅以新病灶评估进行疗效分类,而非依赖SUV指标。
要点
- 靶病灶体积减少≥40%且无新病灶定义为部分缓解
- 靶病灶体积增加≥40%或出现新病灶定义为疾病进展
- 完全缓解要求病理性示踪剂摄取完全消失
核心结论
- 该框架提出主要依据生长抑素受体表达靶病灶的体积变化并辅以新病灶评估进行疗效分类,而非依赖基于SUV的指标。
- 该框架尚未经过生存结局验证,但为临床试验和常规实践中统一基于生长抑素受体PET的疗效评估提供了务实基础。
研究设计与样本
- 制定机构为欧洲神经内分泌肿瘤学会,由EANM和NANETS背书。
- 采用结构化改良德尔菲流程,34位来自核医学、放射学、肿瘤学、内分泌学、外科学及相关学科的国际专家参与。
- 经四轮迭代评估76条声明,共识定义为至少75%同意。
诊断标准与关键数值
- 部分缓解定义为靶病灶体积减少至少40%且无新病灶。
- 疾病进展定义为靶病灶体积增加至少40%或出现新病灶。
- 完全缓解要求病理性示踪剂摄取消失。
- 引入「未经证实的疾病进展」类别,适用于需要短期间隔重新评估的模棱两可病例。
临床应用与阅片要点
- 阅片时应优先报告生长抑素受体表达靶病灶的体积变化百分比,并明确有无新病灶。
- 对模棱两可的疑似进展病例可归入「未经证实的疾病进展」,建议短期间隔重新评估后再确认。
- 报告疗效分类时需结合新病灶评估,不能仅依据靶病灶体积变化。
局限性
- 该框架尚未针对生存结局进行验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Somatostatin receptor PET imaging is integral to the management of patients with neuroendocrine tumours (NETs), yet standardised criteria for therapy response assessment with the use of this modality are not available. This Policy Review reports the development of the European Neuroendocrine Tumor Society somatostatin receptor PET response assessment framework, established through a structured modified Delphi process coordinated by the European Neuroendocrine Tumor Society. 34 international experts from nuclear medicine, radiology, oncology, endocrinology, surgery, and related disciplines participated in four iterative rounds evaluating 76 statements, with consensus defined as at least 75% agreement. The framework proposes response categorisation based primarily on volumetric changes in somatostatin receptor-expressing target lesions, complemented by assessment of new lesions, rather than reliance on standardised uptake value-based metrics. Partial response is defined by at least 40% reduction in target lesion volume without new lesions, whereas progressive disease is defined by at least 40% volume increase of target lesions or the emergence of new lesions. Complete response requires absence of pathological tracer uptake, and a category of unconfirmed progressive disease is introduced for equivocal cases warranting short-interval reassessment. Although not yet validated against survival outcomes, this expert-derived framework (SSTR-PeRForm) provides a pragmatic foundation for harmonising somatostatin receptor PET-based response assessment in clinical trials and routine practice and represents a key step towards outcome-based validation.
引用
- Deroose, Leupe, Hicks, et al. Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS). Lancet Oncol. 2026. PMID: 42398521. doi:10.1016/S1470-2045(26)00145-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。